Terapias futuras en el lupus eritematoso sistémico
DOI:
https://doi.org/10.31053/1853.0605.v68.n2.21537Palabras clave:
lupus eritematoso sistémicoResumen
El Lupus eritematoso sistémico (LES) es el modelo de enfermedad autoinmune sistémica caracterizada por el compromiso de múltiples órganos y actividad de la enfermedad fluctuante. El pronóstico del LES mejoró en las últimas décadas en forma significativa y contribuyeron en este avance no sólo la posibilidad de mayores opciones terapéuticas, sino otros factores como el desarrollo de estrategias relacionadas a la prevención y el tratamiento de los factores de riesgo cardiovascular, el control de infecciones y la inmunización.
Descargas
Referencias
Wallace D. Management of Lupus Evrythematosus recent insights. Curr. Opin. Reumatol. 2002; 14 :212-219
Urowitz, MB and GladmanD.D How to improve morbidity and mortality in Lupus. Rheumatology 2000.39; 238-244
Wallace DJ. What’s new in the management of lupus since 2000?. J Clin Rheumatol 2006;12: 307-13
Mount GR, Gilliand WR. Emerging biological therapies in systemic lupus erythematosus. Clinical Pharmacology & Therapeutics 2008;83: 167-171
Schneider, M. Exploring new territory: considering the future. Lupus 2007;16: 221-226
Looney. RJ, Anolik J, Sanz I. New Therapies for SLE: celular targets. Rheum. Dis Clin North Am 2006;32: 201-215
Reff ME, Carner K, Chambers KS et al. Depletion of B cells in vivo by a chimec mouse human monoclonal antibody to CD20. Blood 1994;83: 435-45
Alas A, Ng CP, Bonavida B. Rituximab modifies the cisplatinmitochondrial signalling pathway, resulting in apoptosis in cisplatin non-Hodgkins lymphoma. Clin Cancer Res 2002; 8:836-48
Anolik JH, Campbell D, Felgar RE ET AL. The relationship of fcgrllla genotype to degree of B cell deplotion by rituximab in the treatment for systemic lupus erythematosus. Arthritis Rheum 2003; 48:455-59
Anolik JH, Barnard J, Cappione A et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthitis Rheum 2004; 50:3580-3590
Maloney DG, Smith B, Rose A. Rituximab mechanism of action and resistance. Semin. Oncol 2002; 29:2-9
Leandro MJ, Edwards JC, Cambridge G et al. An open study of B lymphocyte depletion in systemic lupus eryhematosus. Arthitis Rheum 2002; 46:2673-77.
Leandro MJ, Edwards JC, Cambridge G et al. B-cell depletion in the treatment of the patients whit systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology 2005; 44:1542-45
NG KP, Leandro MJ, Edwards JC, et al. Repeated B cell Depletion in treatment of refratory systemis lupus erythematosus. Ann rheum Dis 2006; 65:942-45
NG KP, Cambridge G, Leonardo MJ et al. B cell depletion therapy in systemic lupus erythematosus: long – term follow up and predictors of respone. Ann Rheum Dis 2007; 66:1259-62
Looney RJ, Anolik H, Campbell D et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I-II dose escalation trial of rituximab. Arthitis Rheum 2004; 50:2580-62
Sfikakis PP, Boletis JN, Lionaki S, ET AL. Remision of proliferative lupus nephritis following B cell depletion therapy is preceded by dwon-regulation of the T cell costimulatory molecule CD40 ligan: an open label trial. Arthritis Rheum 2005; 52:501-13
Gunnarsson I, Sundelin B, Jonsdottir T et al. Histopathologic and clinic outcome of rituximab treatment un patients with cyclophosphamide – resistant proliferative lupus nephritis. Arthtitis Rheum 2007; 56:1263-72
Vigna-Perez M, Hernandez-Castro B, Paredes-Sharopulos O et al. Clinic and immunological effects of rituximab in patientss with lupus nephritis refractory to conventional therapy. Arthitis Res Ther 2006; 8:R83
Catapano F, Jones R, Chaudhry A et al. Remission, relapse and re-treatment of 26 SLE patients with rituximab. Lupus 2008; 17:015
Bhat P, Radhakrishnan J. B lymphocytes and lupus nephritis: New insigths in to pathogenesis and targeted therapies. Kidney International 2008; 73:261-268.
Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized , double.blind, phase II/III systemic lupus erythematosis evaluation of rituximab trial. Arthritis Rheum 2010; 62: 222-33.
n BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis : the lupus nephritis assessment with rituximab (LUNAR) study. Arthritis Rheum 2009,69: 429.
Ramos Casals M, Soto MJ, Cuadrado MJ, Khamashta MA.Rituximab in Systemic Lupus Erythematosus : A systematic review of off label use in 188 cases. Lupus 2009;18:767-76.
Catuogno M et al. FERUM sickness associated with rituximab in a patient with hepatitis C virus related mixed cryoglobulinaemia. Rheumatology (Oxford)2005,44:406.
Calabrese LH, Molloy ES, Hauang D et al. Progressive multifocal leukoencephalopathy in rheumatic disease. Arthritis Rheum 2007; 56:2116-2128
Beger JR, Koralnik IJ. Progressive multifocal leukoencephalopaty and natalizumab-unforeseen consequences. N Engl J Med 2005; 353:414-16
Tedder TF, Tuscano J, Sato S et al. CD22, a B lymphocty-specific adhesión molecule that regulates antigen receptor signalling. Annu Rev Immunol 1997; 15:481-504
Dorner T, Kaufmann J, Wegener WA et al. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus eryhtematosus. Arthritis Res Ther 2006; 8:R74.
Isenberg DA. Treating patients with B-cell depletion. Lupus 2008; 17:400-404
Thompson JS, Bixler SA, Qian F et al. BAAF-R, a novel TNF receptor that specifically interacts with BAAF. Science 2001; 293:2108-11
Moore PA, Belvedere O, Orr A et al. BLyS: Member of the tumor necrosis factor family and B lymphocyte simulator. Science 1999; 285:260-63
Roschke V, Sosnovtseva S, Ward CD et al. BLyS and APRIL from biologiclly active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. J immunol 2002; 169:4314-4321
Stohl W, Metyas S, Tan SM et al. C Lymphocyte stimulator over-expression in patients with systemic lupus erythematosus: longitunidal observations. Arthritis Rheum 2003; 48:3475-3486
Furie R, Sthol W, Ginzler E, et al. Safety pharmacokinetic and pharmacodynamic results of a phase I single and doublé dose escalation study of lymphostat-B (human monoclonal anti-body to BLyS) in SLE patients. Arthritis Rheum 2003; 48:S377
Petri M, Furie R, Ginzler EM, et al. Belimumab (fully human monoclonal antibody to BLyS) improved or stabilized Systemic Lupus erythematosus (SLE) disease a activity over 2.5 years of therapy. Lupus 2008; 17:016
Ginzler EM, Chatham W, Stohl W et al. Correlation of biomarker changes with clinical improvement over 2.5 years of Belimumab (fully human monoclonal antibody to BLyS) Therapy in systemic lupus erythematosus (SLE) patients. Lupus 2008; 17:031
Furie R, Petri M, Zamani O,et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63:3918-30.
Dall Era M, Chakravarty E, Wallace D, Et Al. Reduced B Lymphocyte and immunoglobulin levels after atacicep treatment in patients with SLE: results of a multicenter, phase IB, doublé blind, placebo controlled, dose-escalating trial. Arthritis Rheum 2007; 56:4142-50
Papp KA, Henniger E. Evaluation of efazumab using safe psoriasis control. BCM Dematol 2006; 6:8
Usmani N, Goodfield M. Efalizumab in the treatment of discoid lupus erythematosus. Arch Dermatol 2007; 143:873-77
Janeway CA, Bottomly K. Signals and signs for lymphocyte responses. Cell 1994; 76:275-85
Boumpas DT, Furie r, Manzi S et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferaative lupus glomerulonephritis. Arthritis Rheum 2003; 48:719-727
Kalunian KC, Davis JC, Merrill JT et al. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a radomized, doublé blind, placebo control study. Arthritis Rheum 2002; 46:3251-3258
Davidson A, Diamond B, Wofsy D et al. Block and tackle: CTLA4lg takes on lupus. Lupus 2005; 14:197-203
Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA4lg. Science 1994; 265:1225-27
Daikh DI, Wofsy D. Cutting edge: reversal or murine lupus nephiritis with CTLA4lg and cyclophosphamide. J Immunol 2001; 166:2913-16
Cunnane G, Chan OT, Cassafer G et al. Prevention of renal damage in murine lupus nephiritis by CTLA4 and cyclophosphamide. Arthritis Rheum 2004; 50:1539-48
Lipsky E. Interleukin 6 and rheumatic diseases. Arthritis Research and therapy 2006; 8 Suppl2.
Shirota Y, Yarbora C, Sims G et al. The impact of in vitro antireceptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus. Arthritis Rheum 2005; 52:S697
Tahir H, Isenberg D. Novel therapies in lupus nephritis lupus 2005; 14:77-82
Aringer M, Graninger WB, Sreiner G et al. Safety and efficacy of tumor necrosis factor alpha blockade in systematic lupus erythematosus: an open-label study. Arthritis Rheum 2004; 50:3161-69
Bao L, Osawe I, Puri T et al. C5a promotes development of experimental lupus nephritis wich can be blocked with a specific receptor antagonist. Eur J Immunol 2005; 35:2496-2506.
Molina H. Update on complement in the pathogenesis of SLE. Curr Op Rheum 2002; 14:492-7
Jones DS, Batstad PA, Field MJ et al. Immunospecific reduction of antioligonucleotide antibody-firming cells with tetrakisoligonucleotide conjugate (LPJ394), a therapeutic candidatrfor the treatment of lupus nephritis. J Med Chem 1995; 38:2138-44
Cardiel MH. Abetimus sodium: a new therapy for delaying the time to, and reducing the indence of, renal flare and/or major systemic lupus erythematosus flares in patients with systemic lupus erythematosus who have a history of renal disease. Expert Opin Investig Drugs 2005; 14:77-88
Weisman MH, Bluestein HG, Berner CM et al. Reduction in circulating dsDNA antibody titer after administration of LJP 394. J Rheumatol 1997; 24:314-18
58. Furie RA, Cash JM, Cronin ME et al. Treatment of systemic lupus erythematosus with LJP 294. J Rheumatol 2001; 28:257-265
Strand V, Aranow C, Cardiel MH et al. Imrpovement in health-related quality of life in systematic lupus evythematosus patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placebo. Lupus 2003; 12:677-686
Alarcon Segocia D, Tumalin JA, Furie RA et al. LJP 394 for the prevention of renal flare in pantients with systemic lupus evythematosus: results from a randomized, doublé blind, placebo controlled study. Arthritis Rheum 2003; 48:442-454
Luger D, Dayan M, Zinger H et al. A peptide base don the complementarity determining región 1 of a human monoclonal autoantibody ameliorates spontaneous and induced lupus manifestations in correlation with cytokine immunomodulation. J Clin Immunol 2004; 24:579-90
Roonblom L, Pascual V. The innate immune system in SLE: type I interferons and dendritic cells. Lupus 2008; 17:394-99
Wallace DC, Petri M, Olsen N et al. MEDI-545, an anti-interferin alpha monoclonal antibody, shows evidence of clinical activity in systematic lupus erythematosus. Arthritis Rheum 2007; 56:S526-S527.
Blomberg S, eloranta ML, Magnusson M et al. Expression of the marñers BDCA-2 and 4 production of interferón by plasmocitoid dendritic dell in systemic lupus erythematosus. Arthritis Rheum 2003; 48:2524-2532
Lafyatis R, Marshak-Rothistin A. Toll like receptors and innate immune responses in systemic lupus erythematosus. Arthritis Res Ther 2007; 9:222-228
Furst, D Stem cell transplantion for autoinmune disease: progress and problems. Curr.Op.Rheum 2002;14:220-24
Petri M, Jones RJ, Brodsky RA. High dose cyclophosphamide without stem cell trasplantion in systemic lupus erythematosus. Arthritis & Rheum 2003; 48:166-75.
Descargas
Publicado
Número
Sección
Licencia
Derechos de autor 2011 Universidad Nacional de Córdoba
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial 4.0.
Se permite la generación de obras derivadas siempre que no se haga con fines comerciales. Tampoco se puede utilizar la obra original con fines comerciales.
Cómo citar
